地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 国浩律师（杭州）事务所 关 于 万邦德医药控股集团股份有限公司 2024 年年度股东大会 法律意见书 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二五年五月 国浩律师（杭州）事务所 法律意见书 国浩律师（杭州）事务所 关 于 万邦德医药控股集团股份有限公司 2024 年年度股东大会 法律意见书 致：万邦德医药控股集团股份有限公司 本法律意见书仅用于为公司本次股东大会见证之目的，不得用于其他任何目 的或用途。本所同意，公司将本法律意见书作为公司本次股东大会的公告材料， 随其他需公告的信息一起向公众披 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-035 万邦德医药控股集团股份有限公司 关于董事会秘书辞职暨聘任副总经理及董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 电子邮件：wbdzy@wepon.cn 一、董事会秘书辞职情况 万邦德医药控股集团股份有限公司（以下简称"公司"）董事会于近日收到 公司董事会秘书刘同科先生的书面辞职报告。因工作调整原因，刘同科先生任职 岗位由公司副总经理、董事会秘书调整为公司常务副总经理，提请辞去公司第九 届董事会的董事会秘书职务。根据《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关法律法规、规范性文件及《公司章程》的规 定，刘同科先生的辞职申请自辞职报告送达董事会之日起生效。辞职后，刘同科 先生将继续在公司任董事及常务副总经理职务，其辞职董事会秘书职务的事项不 会影响公司的日常经营和相关业务的管理运作。 截至本公告披露日，刘同科先生未直接持有公司股份，不存在应当履行而未 履行的承诺事项。 刘同科先生在担任公司董事会秘书期间恪尽职守、勤勉尽责，公司董事会对 刘同科先 ...

Financial Performance - In 2024, the company achieved operating revenue of 1.443 billion, a year-on-year decrease of 6.39% [3] - Net profit attributable to shareholders increased by 12.66% to 55.441 million [3] - The pharmaceutical sector's price adjustments in response to national policies have begun to mitigate the impact of collective procurement [3] Business Segments - The medical device segment has expanded its market presence, covering 80% of provinces and over 50 cities [4] - The South African subsidiary has shown significant growth, leveraging local distribution networks to introduce domestic medical equipment to the African market [4] Research and Development - The company is focusing on innovative drugs, generic drugs, raw materials, and traditional Chinese medicine, with a dedicated R&D team of 120 [6] - Key projects include clinical trials for drugs targeting Alzheimer's and other serious conditions, with FDA approvals for several products [6] Investor Relations - The company emphasizes transparency and interaction in investor relations, utilizing various communication channels to ensure effective information dissemination [7] - Future plans include enhancing digital capabilities and conducting scenario-based roadshows to strengthen investor understanding of the company's growth logic [7]

Core Points - Wanbangde's stock closed at 5.72 yuan on May 12, down 1.04%, with a rolling PE ratio of 83.70 times and a total market value of 3.499 billion yuan [1] - The average PE ratio for the chemical pharmaceutical industry is 45.46 times, with a median of 26.94 times, placing Wanbangde at the 127th position in the industry ranking [1] - On May 12, the net inflow of main funds into Wanbangde was 934,100 yuan, showing an overall inflow trend over the past five days, totaling 245,800 yuan [1] Company Overview - Wanbangde Pharmaceutical Holdings Co., Ltd. specializes in the research, development, production, and sales of modern traditional Chinese medicine, chemical raw materials, and chemical preparations, as well as providing high-end medical device research, medical equipment services, and hospital engineering services [1] - The main products include cardiovascular system products, neurological system products, respiratory system products, digestive system products, psychiatric system products, orthopedic implants, medical devices, hospital engineering services, disposable sterile medical polymer consumables, and protective equipment [1] Financial Performance - In the first quarter of 2025, the company reported operating revenue of 315 million yuan, a year-on-year decrease of 26.58%, and a net profit of 15.2018 million yuan, a year-on-year decrease of 47.29%, with a sales gross margin of 33.85% [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002082 证券简称：万邦德 公告编号：2025-032 万邦德医药控股集团股份有限公司 关于参加2025年浙江辖区上市公司 万邦德医药控股集团股份有限公司（以下简称"公司"）于2025年4月29日披露了《2024年年度报告》。 为进一步加强与投资者的交流互动，公司将参加由浙江证监局、浙江上市公司协会、深圳市全景网络有 限公司联合举办的"2025年浙江辖区上市公司投资者网上集体接待日暨2024年度业绩说明会"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站(https://rs.p5w.net)，或关注微信公 众号:全景财经，或下载全景路演APP,参与本次互动交流，活动时间为2025年5月13日(周二)15:00- 17:00。 公司董事长兼总经理赵守明先生，副总经理兼董事会秘书刘同科先生，独立董事周岳江先生（具体参会 人员以实际出席为准）将就公司2024年年度报告和经营情况，与投资者进行沟通与交流，欢迎广大投资 者踊跃参与! 为充分尊重投资者、提升交流的针对性，现提前向投资者公开征集问题，广泛听取投资者的 ...

关于参加 2025 年浙江辖区上市公司投资者网上集体接待日 暨 2024 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）于2025年4月29日披 露了《2024年年度报告》。为进一步加强与投资者的交流互动，公司将参加由浙 江证监局、浙江上市公司协会、深圳市全景网络有限公司联合举办的"2025年浙 江辖区上市公司投资者网上集体接待日暨2024年度业绩说明会"，现将相关事项 公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (https://rs.p5w.net)，或关注微信公众号:全景财经，或下载全景路演APP,参与 本次互动交流，活动时间为2025年5月13日(周二)15:00-17:00。 证券代码：002082 证券简称：万邦德 公告编号：2025-032 万邦德医药控股集团股份有限公司 万邦德医药控股集团股份有限公司 董 事 会 二〇二五年五月八日 公司董事长兼总经理赵守明先生，副总经理兼董事会秘书刘同科先生，独立 董事周岳江先生（具体参会人员以实际出席为 ...

经济观察网讯 5月6日重点关注的财经要闻与资本市场大事： （原标题：今日看点｜北交所为试点股票启用新证券代码） 5月6日，21家公司共发布21个股票回购相关进展。其中，2家公司首次披露股票回购预案，14家公司披 露股票回购实施进展，5家公司回购方案已实施完毕。 从首次披露回购预案来看，当日共1家公司股票回购预案金额超千万。科思科技、毅昌科技回购预案金 额最高，分别拟回购不超5000.0万元、66.36万元。从回购实施进展来看，美的集团、长春高新、九安医 疗回购金额最高，分别回购5.54亿元、4.0亿元、3.7亿元。从已完成回购来看，当日共4家公司回购金额 超千万。华工科技、天茂集团、万邦德已完成回购金额最高，分别回购3.95亿元、9998.26万元、 5998.85万元。 4、美国3月贸易帐、欧元区3月PPI月率等数据将公布。 （数据来源Wind，内容不构成任何投资建议） 1、北交所为试点股票启用新证券代码 近日，北交所发布通知，北交所存量上市公司代码切换试点工作总体准备就绪，拟于2025年5月6日正式 上线。根据通知，2025年5月1日至2025年5月5日期间，北交所组织开展代码切换与通关测试，自2025年 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-031 万邦德医药控股集团股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、万邦德医药控股集团股份有限公司（以下简称"公司"）本次注销的回 购股份数量为 5,000,000 股，占注销前公司总股本的 0.81%。本次注销完成后， 公司总股本将由 616,689,055 股变更为 611,689,055 股。 2、经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份 注销手续已于 2025 年 4 月 29 日办理完成。 二、回购股份注销情况 鉴于公司回购股份存续时间已满三年，且未在有效期内完成股权激励或员工 持股计划。根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等法律法规和规范性文件及《公司章程》的有关规定，现就 本次回购股份注销完成的具体情况公告如下： 一、回购股份的实施情况 公司于 2021 年 3 月 14 日召开 ...

Financial Performance - The company's revenue for Q1 2025 was ¥315,110,184.08, a decrease of 26.58% compared to ¥429,172,675.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,201,816.26, down 47.29% from ¥28,838,483.33 year-on-year[5] - The basic earnings per share decreased by 46.57% to ¥0.0249 from ¥0.0466 in the same period last year[5] - Total operating revenue decreased to ¥315,110,184.08 from ¥429,172,675.52, representing a decline of approximately 26.6% year-over-year[19] - Net profit for the period was ¥11,227,654.31, down from ¥24,958,440.91, indicating a decline of approximately 55.1% year-over-year[19] - Total comprehensive income attributable to the parent company's owners was CNY 16,503,593.60, a decrease from CNY 28,166,335.28 in the previous period, representing a decline of approximately 41.6%[21] - Basic and diluted earnings per share were both CNY 0.0249, down from CNY 0.0466, indicating a decrease of about 46.5%[21] Cash Flow - The net cash flow from operating activities was -¥17,285,740.15, a decline of 117.05% compared to ¥101,357,363.89 in the previous year[5] - The company reported a decrease in sales expenses to ¥41,035,894.57 from ¥68,543,940.69, reflecting a cost-cutting strategy[19] - Net cash flow from operating activities was negative CNY 17,285,740.15, compared to positive CNY 101,357,363.89 in the previous period, reflecting a significant decline[22] - Cash inflow from investment activities totaled CNY 2,872,578.72, an increase from CNY 1,967,181.53 year-over-year[22] - Cash outflow from investment activities was CNY 25,332,665.92, down from CNY 166,170,288.90, indicating a reduction of approximately 84.8%[22] - Net cash flow from financing activities was negative CNY 59,487,257.84, compared to positive CNY 27,980,960.68 in the previous period, showing a reversal in cash flow[22] - The ending balance of cash and cash equivalents was CNY 44,302,664.88, down from CNY 183,656,176.46, a decrease of about 76.1%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,271,069,770.54, a decrease of 1.30% from ¥4,327,397,080.53 at the end of the previous year[5] - Total liabilities decreased to ¥1,501,478,651.87 from ¥1,570,954,359.63, showing a reduction of about 4.4%[18] - Non-current liabilities totaled ¥332,227,294.64, an increase from ¥254,681,402.98, representing a growth of approximately 30.4%[18] - As of the end of the reporting period, the company's total current assets amounted to approximately CNY 1.75 billion, a decrease from CNY 1.80 billion at the beginning of the period[16] Government Support and Subsidies - The company received government subsidies amounting to ¥27,691,508.52, which positively impacted the financial results[6] Research and Development - Research and development expenses were ¥12,774,780.81, slightly down from ¥13,058,050.61, indicating a continued commitment to innovation despite revenue challenges[19] - Wanbangde Pharmaceutical received approval from the National Medical Products Administration for the supplement application of Cefaclor granules, which is considered to have passed the consistency evaluation of generic drug quality and efficacy, enhancing market competitiveness[11] - The company obtained FDA approval for clinical trials of WP107 (Huperzine A oral solution) for treating generalized myasthenia gravis and WP103 (Huperzine A injection) for treating neonatal hypoxic-ischemic encephalopathy, marking a significant step in new drug development[12] - The FDA granted orphan drug designation for Mecobalamin for the treatment of Amyotrophic Lateral Sclerosis (ALS), providing various incentives for drug development and commercialization in the U.S. market[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 27,646, with the largest shareholder holding 31.37% of the shares[9] - The company completed the repurchase of 5 million shares in March 2022, which were subsequently canceled due to the inability to complete the employee stock ownership plan within the effective period[15]

Group 1 - The core viewpoint of the news is that Wanbangde's stock performance and financial metrics indicate a mixed outlook, with a high PE ratio compared to industry averages and a decline in revenue [1][2] - As of April 29, Wanbangde's closing price was 5.81 yuan, with a PE ratio of 64.63, significantly higher than the industry average of 45.68 [1][2] - The company's total market capitalization is 3.583 billion yuan, ranking 119th in the chemical pharmaceutical industry [1][2] Group 2 - In terms of capital flow, Wanbangde experienced a net outflow of 8.5344 million yuan on April 29, with a total outflow of 9.6829 million yuan over the past five days [1] - The latest financial results for 2024 show that the company achieved a revenue of 1.443 billion yuan, a year-on-year decrease of 6.39%, while net profit was 55.441 million yuan, an increase of 12.66% [1] - The company's gross profit margin stands at 41.83%, indicating a relatively healthy profitability despite the revenue decline [1]